文献类型：期刊文献

英文题名：Integrating Chinese and western medicine for COVID-19: A living evidence-based guideline (version 1)

作者：Ge, Long[1,2,3,4];Zhu, Hongfei[1,2];Wang, Qi[1,2];Li, Mengting[1,2];Cai, Jianxiong[5,6,7];Chen, Yang[8];Chen, Yaolong[3,4,9,10];Ding, Banghan[5];Fang, Bangjiang[11];Fei, Yutong[12];Feng, Jihong[13];Guo, Xinfeng[5,6,7];Jiang, Rongmeng[14];Jiang, Yuyong[14];Li, Guiwei[15];Li, Xiuhui[16];Li, Xucheng[17];Liang, Qun[18];Liu, Jian[19];Liu, Jianping[12];Liu, Qingquan[20];Liu, Shaonan[5,6,7];Lu, Yun[21];Miao, Qing[22];Qi, Wensheng[23];Shang, Hongcai[24];Shi, Liqing[25];Tan, XingHua[26];Tang, Xudong[27];Wang, Xianbo[14];Wang, Xiaojun[16];Xia, Wenguang[28];Yang, Kehu[2,3,4,9];Yang, Lihong[5,6,7];Ye, Yongan[24];Zhou, Qi[10];Zhang, Hongchun[29];Zhang, Junhua[30];Zhang, Zhiming[31];Zhang, Zhongde[5];Zou, Xu[5];Li, Jun[5];Wu, Darong[5,6,7]

第一作者：Ge, Long

通信作者：Li, J[1];Wu, DR[2]

机构：[1]Lanzhou Univ, Sch Publ Hlth, Dept Social Med & Hlth Management, Lanzhou, Peoples R China;[2]Lanzhou Univ, Evidence Based Social Sci Res Ctr, Sch Publ Hlth, Lanzhou, Peoples R China;[3]WHO Collaborating Ctr Guideline Implementat & Kno, Lanzhou, Peoples R China;[4]Lanzhou Univ, Chinese GRADE Ctr, Lanzhou, Peoples R China;[5]Guangdong Prov Hosp Chinese Med, Guangzhou 510120, Peoples R China;[6]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China;[7]Guangdong Prov Acad Chinese Med Sci, Guangzhou, Peoples R China;[8]Guizhou Univ Tradit Chinese, Affiliated Hosp 1, Guiyang, Peoples R China;[9]Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Peoples R China;[10]Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China;[11]Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai, Peoples R China;[12]Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China;[13]Tianjin Univ Tradit Chinese Med, Affiliated Hosp 2, Tianjin, Peoples R China;[14]Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China;[15]Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin, Peoples R China;[16]Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China;[17]Wuhan Hosp Tradit Chinese Med, Wuhan, Peoples R China;[18]Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Harbin, Peoples R China;[19]Lanzhou Univ, Hosp 1, Lanzhou, Peoples R China;[20]Capital Med Univ, Beijing Tradit Chinese Med Hosp, Beijing, Peoples R China;[21]Chengdu Univ Tradit Chinese Med, Affiliated Hosp, Chengdu, Peoples R China;[22]China Acad Chinese Med Sci, Xiyuan Hosp, Beijing, Peoples R China;[23]China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China;[24]Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China;[25]Beijing Univ Chinese Med, Dept Resp Med, Dongfang Hosp, Beijing, Peoples R China;[26]Guangzhou Eighth Peoples Hosp, Guangzhou, Peoples R China;[27]China Acad Chinese Med Sci, Beijing, Peoples R China;[28]Hubei Prov Hosp Integrated Tradit Chinese & Weste, Wuhan, Peoples R China;[29]China Japan Friendship Hosp, Beijing, Peoples R China;[30]Tianjin Univ Tradit Chinese Med, Evidence Based Med Ctr, Tianjin, Peoples R China;[31]Gansu Univ Tradit Chinese Med, Affiliated Hosp, Lanzhou, Peoples R China

第一机构：Lanzhou Univ, Sch Publ Hlth, Dept Social Med & Hlth Management, Lanzhou, Peoples R China

通信机构：[1]corresponding author), Guangdong Prov Hosp Chinese Med, Guangzhou 510120, Peoples R China;[2]corresponding author), Guangzhou Univ Chinese Med, State Key Lab Dampness Syndrome Chinese Med, Affiliated Hosp 2, Guangzhou 510120, Peoples R China.

年份：2021

卷号：14

期号：4

起止页码：313

外文期刊名：JOURNAL OF EVIDENCE BASED MEDICINE

收录：;Scopus(收录号：2-s2.0-85116749221);WOS:【SCI-EXPANDED(收录号:WOS:000705256400001)】；

基金：China National Centre for Biotechnology Development, Grant/Award Numbers: 2019YFC1709805, 2019YFC1709802; State Key Laboratory of Dampness Syndrome of Chinese Medicine, Grant/Award Numbers: ZH2019ZZ04, SZ2020ZZ09

语种：英文

外文关键词：COVID-19; evidence-based practice; living guideline; recommendation; SARS-CoV-2; traditional Chinese medicine

摘要：Background The coronavirus disease 2019 (COVID-19) has turned into a pandemic and resulted in huge death tolls and burdens. Integrating Chinese and western medicine has played an important role in the fight against the COVID-19 pandemic. Purpose We aimed to develop a living evidence-based guideline of integrating Chinese and western medicine for COVID-19. Study design Living evidence-based guideline. Methods This living guideline was developed using internationally recognized and accepted guideline standards, dynamically monitoring the release of new clinical evidence, and quickly updating the linked living systematic review, evidence summary tables, and recommendations. Modified Delphi method was used to reach consensus for all recommendations. The certainty of the evidence, resources, and other factors were fully considered, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to rate the certainty of evidence and the strength of recommendations. Results The first version of this living guidance focuses on patients who are mild or moderate COVID-19. A multidisciplinary guideline development panel was established. Ten clinical questions were identified based on the status of evidence and a face-to-face experts' consensus. Finally, nine recommendations were reached consensus, and were formulated from systematic reviews of the benefits and harms, certainty of evidence, public accessibility, policy supports, feedback on proposed recommendations from multidisciplinary experts, and consensus meetings. Conclusion This guideline panel made nine recommendations, which covered five traditional Chinese medicine (TCM) prescription granules/decoction (MXXFJD, QFPD, XFBD, TJQW, and JWDY), three Chinese patent medicines (LHQW granules/capsule, JHQG granules, and LHQK granules), and one Chinese herbal injection (XBJ injection). Of them, two were strongly recommended (LHQW granules/capsule and QFPD decoction), and five were weakly recommended (MXXFJD decoction, XFBD decoction, JHQG granules, TJQW granules, and JWDY decoction) for the treatment of mild and moderate COVID-19; two were weakly recommended against (XBJ injection and LHQK granules) the treatment of mild and moderate COVID-19. The users of this living guideline are most likely to be clinicians, patients, governments, ministries, and health administrators.